← FDA DRUG APPROVALS

FDA ANDA · ANDA088328

LIDOCAINE HYDROCHLORIDE

Sponsor: HOSPIRA

APPLICATION
ANDA088328
TYPE
ANDA
ORIGINAL APPROVAL
1984-05-17
LATEST ACTION
2020-03-19
ROUTE
INFILTRATION, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

LIDOCAINE HYDROCHLORIDEPrescription
LIDOCAINE HYDROCHLORIDE 0.5% · INJECTABLE · INJECTION

Approval history

2020-03-19Labeling · Supplement 29 · standardAP
2020-03-19Labeling · Supplement 30 · standardAP
2010-04-16Labeling · Supplement 17AP
1996-10-22Manufacturing (CMC) · Supplement 7AP
1996-10-03Manufacturing (CMC) · Supplement 8AP
1990-10-10Labeling · Supplement 4AP
1988-12-12Labeling · Supplement 3AP
1986-08-15Manufacturing (CMC) · Supplement 2AP
1985-04-18Manufacturing (CMC) · Supplement 1AP
1984-05-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →